Oluyemi Okupe Sells 29,277 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 29,277 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $29.95, for a total transaction of $876,846.15. Following the transaction, the chief financial officer directly owned 236,527 shares of the company’s stock, valued at $7,083,983.65. This represents a 11.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.82, for a total value of $354,860.66.
• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.99, for a total value of $148,090.62.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $2.00 on Wednesday, reaching $28.43. 11,816,307 shares of the stock traded hands, compared to its average volume of 24,193,828. The stock’s 50-day moving average price is $29.87 and its 200-day moving average price is $27.88. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The firm has a market cap of $6.63 billion, a price-to-earnings ratio of -45.13 and a beta of 2.42. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $65.30.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same quarter in the prior year, the firm earned $0.17 EPS. The firm’s quarterly revenue was up 38.2% on a year-over-year basis. Equities analysts forecast that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: Several firms, including Kaplan Fox, Faruqi & Faruqi, Rosen Law Firm and others, reminded investors that November 2, 2026 is the deadline to seek lead-plaintiff status in a federal securities class action covering purchases of HIMS securities from August 4, 2025, through July 29, 2026. Kaplan Fox investor notice
• Negative Sentiment: The lawsuit alleges that Hims & Hers and certain executives made material misstatements or omissions regarding allegedly deceptive and unlawful privacy and billing practices. The claims reportedly stem in part from allegations in a Federal Trade Commission complaint. Hagens Berman lawsuit notice
• Negative Sentiment: The concentrated publicity increases reputational, regulatory and potential litigation-cost concerns for HIMS. Investors should note that the allegations have not been proven, and the notices do not indicate the likely damages, outcome or financial impact of the case.

Analysts Set New Price Targets

HIMS has been the topic of a number of recent research reports. Citigroup decreased their price objective on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Weiss Ratings restated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Truist Financial lifted their price objective on Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a report on Monday, August 24th. Finally, TD Cowen upped their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $32.43.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after purchasing an additional 608,950 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after buying an additional 2,877,550 shares during the last quarter. Norges Bank acquired a new position in Hims & Hers Health during the 4th quarter worth about $62,153,000. Clear Street Group Inc. grew its holdings in Hims & Hers Health by 23.6% during the 4th quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company’s stock worth $61,832,000 after acquiring an additional 363,893 shares during the last quarter. Finally, State of Michigan Retirement System grew its holdings in Hims & Hers Health by 13.7% during the 1st quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock worth $48,549,000 after acquiring an additional 280,900 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.